MicroRNAs as serum biomarkers in Becker muscular dystrophy. Issue 17 (26th July 2022)

• Record Type: Journal Article
• Authors: Gagliardi, Delia; Rizzuti, Mafalda; Brusa, Roberta; Ripolone, Michela; Zanotti, Simona; Minuti, Elisa; Parente, Valeria; Dioni, Laura; Cazzaniga, Sara; Bettica, Paolo; Bresolin, Nereo; Comi, Giacomo Pietro; Corti, Stefania; Magri, Francesca; Velardo, Daniele
• Is Part Of: Journal of cellular and molecular medicine. Volume 26:Issue 17(2022)
• Page Start: 4678
• Page End: 4685
• Publication Date: 2022-07-26
• Subjects: Becker muscular dystrophy -- biomarkers -- BMD -- miR‐133b -- miRNA -- serum -- skeletal muscle; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.17462
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Becker muscular dystrophy (BMD) is an X‐linked neuromuscular disorder due to mutation in the DMD gene, encoding dystrophin. Despite a wide clinical variability, BMD is characterized by progressive muscle degeneration and proximal muscle weakness. Interestingly, a dysregulated expression of muscle‐specific microRNAs (miRNAs), called myomirs, has been found in patients affected with muscular dystrophies, although few studies have been conducted in BMD. We analysed the serum expression levels of a subset of myomirs in a cohort of 29 ambulant individuals affected by BMD and further classified according to the degree of alterations at muscle biopsy and in 11 age‐matched healthy controls. We found a significant upregulation of serum miR‐1, miR‐133a, miR‐133b and miR‐206 in our cohort of BMD patients, supporting the role of these miRNAs in the pathophysiology of the disease, and we identified serum cut‐off levels discriminating patients from healthy controls, confiming the potential of circulating miRNAs as promising noninvasive biomarkers. Moreover, serum levels of miR‐133b were found to be associated with fibrosis at muscle biopsy and with patients' motor performances, suggesting that miR‐133b might be a useful prognostic marker for BMD patients. Taken together, our data showed that these serum myomirs may represent an effective tool that may support stratification of BMD patients, providing the opportunity of both monitoring disease progression and assessing the treatment efficacy in the context of clinical trials.